India’s Drug Controller May Be Participating in ACTA Discussions
June 21, 2008
Pursuant to our post lamenting the “secrecy” with which the ACTA (Anti Counterfeiting Trade Agreement) negotiations were shrouded, an anonymous source writes to inform us thus:
“I am afraid that the new Indian Drugs Controller General is being briefed about the Treaty , its objectives etc as he has been (unlike any before him) invited to Canada and USA. The Indian Govt has become too inward- concerned to worry about these “conspiracies” concerning IP treaties from the West!”
SpicyIP hasn’t verified this news as yet–but if any of our readers have more information on this, please let us know.
Looks like our DCGI (Drug Controller General of India), Dr Surinder Singh is a hot favourite in the international IP circles now. Not least because he’s been very enthusiastic about framing rules to link up drug regulatory approval with patents. Except that he forgets that there exists something called the Constitution of India, under which any overstepping of statutory bounds is likely to be challenged by a writ petition and struck down by a court!
I have nothing to add to the tip received by Spicy IP, but I would add that the USTR and EC briefing “interested observers” is far from surprising given the ACTA negotiants stated aim to extend the treaty to “interested trade partners” once it’s signed.
Have other officials from non-participating states been briefed on the agreement?